19 results
425
TRML
Tourmaline Bio Inc
26 Sep 23
Business combination disclosure
8:24am
Generated from Medarex transgenic mouse platform 10 Robust existing clinical data package Two Phase 2 studies completed (SLE and Crohn’s) 8 448 … : company reports, publications, FDA review documents, package inserts 12 AE: Autoimmune encephalitis; AMR: Antibody mediated rejection; ASCVD
8-K
EX-99.1
TRML
Tourmaline Bio Inc
26 Sep 23
Regulation FD Disclosure
8:21am
(Study B0151002) Terminal half-life 47-58 days 12 Generated from Medarex transgenic mouse platform 10 Robust existing clinical data package Two Phase 2 … Indication Key: Approved Investigational Source: company reports, publications, FDA review documents, package inserts 12 AE: Autoimmune encephalitis; AMR
425
TRML
Tourmaline Bio Inc
13 Sep 23
Business combination disclosure
9:14am
with high affinity Kd of 6 pM Terminal half-life 47-58 days Generated from Medarex transgenic mouse platform Robust existing clinical data package Two … : company reports, publications, FDA review documents, package inserts AE: Autoimmune Encephalitis; AMR: Antibody-Mediated Rejection; ASCVD: Atherosclerotic
8-K
EX-99.1
7v0w3ydk2
13 Sep 23
Regulation FD Disclosure
9:13am
S-4
EX-10.4
appcn69
19 Jul 23
Registration of securities issued in business combination transactions
7:57pm
8-K
EX-99.2
s0x i37y0y4dehkf1
22 Jun 23
Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement
9:10am
DEF 14A
neifqszc
29 Apr 22
Definitive proxy
4:24pm
10-K
7w7xgg 12
17 Mar 22
Annual report
4:31pm
S-1/A
EX-1.1
a8546ryeqnr3ui
3 May 21
IPO registration (amended)
6:07am
S-1/A
EX-10.7
g4ug24dea2xdtttelgp
3 May 21
IPO registration (amended)
6:07am
- Prev
- 1
- Next